In the recent ruling of Baxalta Inc. v. Genentech, Inc, the Federal Circuit affirmed the District of Delaware’s grant of summary judgment regarding the lack of enablement for broad antibody claims. This judgement upheld the Supreme Court’s precedent set in Amgen Inc. v. Sanofi, maintaining that antibody claims that specify functionality rather than structure lack enablement.
This judgment implies that Federal Circuit could potentially reject broad antibody claims based merely on what the antibody does, emphasizing the need for the descriptive nature of the antibody structure itself. By doing so, it maintains a cautious approach to patenting in the biotech industry, which could have far-reaching implications for antibody-related patents and their litigation.
In the course of its decision, the Federal Circuit paralleled the Supreme Court’s reasoning in Amgen Inc. v. Sanofi, which established the foundational principle underscoring this latest judgment. The principle in question is the necessity for a patent claim to be enabled—that is, for it to clearly elucidate the structure of the antibody, rather than merely its function.
For multinational corporations and law firms in the biotech sector, this decision serves as an important reminder of the necessity for precise definition and enablement in patent filing. As the ruling in Baxalta Inc. v. Genentech, Inc brings to the fore the significance of a comprehensive definition of an antibody, it also lays an emphasis on the inherent connection between the antibody’s structure and its functionality.
This ruling is likely to instigate a shift in patenting strategies, necessitating a transition from function-based filings to a more structural description. Thus, it should be considered as a cautionary precedent by legal professionals and R&D departments in the bio-pharmaceutical industry.